Beijing Minhai Biotechnology Co., Ltd
Quick facts
Phase 3 pipeline
- Act-HIB® · Immunology / Infectious Disease
Act-HIB is a conjugate vaccine that stimulates immune response against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier. - Hib Vaccine Group · Immunology
Hib vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) bacteria, preventing infection. - MCV-AC Vaccine Group · Immunology / Infectious Disease
MCV-AC is a meningococcal conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis to prevent meningococcal disease. - MCV-ACYW135 Vaccine Group · Immunology
MCV-ACYW135 is a meningococcal conjugate vaccine that stimulates immune response against serogroups A, C, Y, and W-135 of Neisseria meningitidis. - Minhai-HIB · Immunology / Infectious Disease
Minhai-HIB is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates immune responses against the polysaccharide capsule of H. influenzae type b bacteria. - MPV-A Vaccine Group · Immunology
MPV-A is a multi-pathogen vaccine designed to provide immunological protection against multiple viral pathogens through stimulation of adaptive immune responses. - MPV-ACYW135 Vaccine Group · Immunology
MPV-ACYW135 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against serogroups A, C, Y, and W-135 of Neisseria meningitidis. - pneumococcal disease prevention
- sIPV+bOPV · Infectious Diseases
This vaccine combines inactivated poliovirus (sIPV) and oral poliovirus vaccine (bOPV) to provide immunity against poliomyelitis. - wIPV · Infectious Diseases
WIPV is a small molecule targeting the SARS-CoV-2 main protease. - wIPV+bOPV · Infectious Disease
WIPV+bOPV is a vaccine that targets the SARS-CoV-2 virus.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Beijing Minhai Biotechnology Co., Ltd portfolio CI brief
- Beijing Minhai Biotechnology Co., Ltd pipeline updates RSS
Frequently asked questions about Beijing Minhai Biotechnology Co., Ltd
What is Beijing Minhai Biotechnology Co., Ltd's pipeline?
Beijing Minhai Biotechnology Co., Ltd has 11 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Act-HIB®, Hib Vaccine Group, MCV-AC Vaccine Group, MCV-ACYW135 Vaccine Group.
Related
- Sector hub: All tracked pharma companies